Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66940-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- RACK1; GNB2L1 antibody
- Antibody type
- Monoclonal
- Description
- RACK1; GNB2L1 antibody (Cat. #66940-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, Mouse, Rat, Pig and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat, Porcine
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1E11A7
- Vial size
- 20ul, 150ul
Submitted references Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression.
CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages.
Neuropilin 1 promotes unilateral ureteral obstruction-induced renal fibrosis via RACK1 in renal tubular epithelial cells.
Photoaffinity Probe Reveals the Potential Target of Harringtonolide for Cancer Cell Migration Inhibition.
Pi Y, Feng Q, Sun F, Wang Z, Zhao Y, Chen D, Liu Y, Lou G
Cell death and differentiation 2023 Nov;30(11):2382-2392
Cell death and differentiation 2023 Nov;30(11):2382-2392
CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages.
Zhang G, Gao Z, Guo X, Ma R, Wang X, Zhou P, Li C, Tang Z, Zhao R, Gao P
The Journal of clinical investigation 2023 Nov 1;133(21)
The Journal of clinical investigation 2023 Nov 1;133(21)
Neuropilin 1 promotes unilateral ureteral obstruction-induced renal fibrosis via RACK1 in renal tubular epithelial cells.
Hou L, Du Y
American journal of physiology. Renal physiology 2023 Dec 1;325(6):F870-F884
American journal of physiology. Renal physiology 2023 Dec 1;325(6):F870-F884
Photoaffinity Probe Reveals the Potential Target of Harringtonolide for Cancer Cell Migration Inhibition.
Zhu TY, Wu XT, Chen C, Liu XQ, Zhu L, Luo JG, Kong LY
ACS medicinal chemistry letters 2022 Mar 10;13(3):449-456
ACS medicinal chemistry letters 2022 Mar 10;13(3):449-456
No comments: Submit comment
No validations: Submit validation data